Drugdu.com expert's response:

 

When exporting APIs, excipients, and peptide APIs, suppliers often receive inquiries like this.

After asking about the product and price, the buyer quickly adds: “Please send COA, GMP and DMF.”

Some suppliers may think the buyer is professional and immediately send all the documents they have. Others may be more cautious, worry about sensitive information, and simply reply: “Available.”

Neither approach is ideal.

When a buyer asks for COA, GMP and DMF at once, it may mean that this is not just a casual price inquiry. The buyer may already be checking whether the product can move forward to purchasing, registration, or supplier qualification. But what documents to send, and how much to share, still depends on the project stage.

First, understand why the buyer needs these documents

Even when buyers ask for the same documents — COA, GMP and DMF — their purpose may be different.

Some buyers only want to confirm whether the supplier has basic documents. Some are helping an end-user pharmaceutical company screen suppliers. Some are preparing for a registration project. Others may simply be collecting documents and prices from many suppliers, while the project itself is still unclear.

So it is not recommended to send all documents right away. You can reply and ask one more question:

“Thank you for your request. We can provide documents for review. May I know your target market and whether this is for supplier qualification, registration or commercial purchase?”

This helps connect the buyer’s document request with the real project stage.

If the buyer is willing to explain the target country, product use, purchasing stage and required document type, this inquiry is worth following up seriously. If the buyer only keeps asking to “send all documents” but refuses to provide any background, the supplier should control how much information is shared.

COA can be provided first, but pay attention to the version and product match

COA is usually one of the first documents buyers ask for. It helps buyers make an initial judgment on quality indicators, test items and batch information.

Before sending a COA, suppliers should check several points:

Whether the product name matches;

Whether the CAS number is consistent;

Whether the specification or quality standard matches;

Whether it is a sample COA or a recent batch COA;

Whether some commercially sensitive information needs to be hidden.

If the buyer is only doing an initial review, suppliers can provide a sample COA or a public version first, and explain:

“Sample COA can be provided for initial review. Recent batch COA can be shared when the specification and project requirement are confirmed.”

This responds to the buyer’s request while avoiding sending all batch documents at the very beginning.

If the buyer has already entered a formal review stage, such as asking for the latest three batch COAs, then the supplier should further confirm the project purpose and purchasing stage before coordinating with the quality team.

For GMP documents, buyers care not only whether they exist, but also who they belong to

When buyers ask for GMP, they usually want to confirm the manufacturer’s quality system and production compliance.

But when sending GMP-related documents, suppliers need to pay attention to one issue: which company, production site, and product scope the GMP document actually covers.

Some trading companies sell products from partner manufacturers. The company name on the platform may not be the same as the GMP certificate holder. If this relationship is not explained clearly, buyers may continue to ask:

Who is the actual manufacturer?

Is this GMP certificate for the same product?

Will the commercial batch be supplied by this manufacturer?

So when sending GMP-related information, suppliers can briefly explain the production relationship: “The GMP document is issued to the manufacturer of this product. We work with this manufacturer for supply and documentation support.”

If the supplier is the manufacturer, they can say: “The product is manufactured at our own facility, and relevant GMP/quality documents can be provided for review.”

The key is to help the buyer understand the relationship between the document holder and the product source.

DMF depends even more on the project stage and should not be sent casually

DMF is different from COA.

COA is mainly used for initial quality review. GMP helps confirm production and quality system status. DMF, however, is often related to registration projects, authorization, and target markets.

If the buyer only asks, “DMF available?”, suppliers should not simply reply “Yes” and send sensitive documents directly.

A better approach is to confirm first:

Which target market is involved;

Whether the buyer is a pharmaceutical manufacturer, importer or registration agent;

Whether the product is for R&D, commercial production or registration;

Whether the buyer needs DMF status information, an LOA, or specific registration support;

Whether a confidentiality agreement is needed.

Suppliers can reply:

“DMF support can be discussed based on the target market and project stage. Could you please confirm the country of registration and whether you need DMF status information or an authorization letter for registration?”

This is more appropriate and also shows that the supplier understands the basic logic of registration-related communication.

Documents can be provided in layers instead of all at once

For new buyers, documents can be shared in different levels.

The first level includes basic product documents, such as product specifications, sample COA, basic specification sheet and packaging information.

The second level includes quality system and supplier qualification documents, such as GMP documents, manufacturer information, quality system files and consecutive batch records.

The third level includes registration-related documents, such as DMF status information, authorization letters, stability data, process-related information or deeper technical documents.

When the buyer is only making an initial inquiry, suppliers can provide the first level of documents. If the project enters supplier qualification, the second level can be provided. If it is clearly a registration project, then the third level can be discussed further.

This approach does not make the buyer feel that the supplier is uncooperative, while also helping the supplier protect important documents.

When replying to buyers, do not only say “Available”

Many suppliers reply like this:

“COA, GMP and DMF are available.”

This is too simple. The buyer still does not know how to move forward.

It can be changed to: “COA and specification can be provided for initial review. GMP-related documents can be shared after confirming the manufacturer and project requirement. For DMF support, please confirm your target market and registration stage, so that we can check the suitable documentation support.”

This reply is a little longer, but it clearly explains the document levels and the next information needed.

If the buyer has a real project, they will continue to provide details. If the buyer is only collecting documents broadly, this round of communication can also help reveal that.

The product page can also explain document support in advance

Many buyers have already checked the product page before sending an inquiry.

If the product page only says “High quality API” or “GMP available,” buyers still need to reconfirm many details.

For key API, excipient and peptide API products, the product page can mention:

COA available;

Specification available;

GMP-related support;

DMF or registration support experience;

Applicable quality standards;

Packaging specifications;

Sample and commercial batch supply support.

There is no need to make all documents public. But buyers should be able to understand how far the supplier can support the project.

Conclusion

When a buyer asks for COA, GMP and DMF at the same time, the inquiry may have moved from a basic price request to a documentation review stage.

But documents should not simply be sent as quickly, as fully, and as extensively as possible.

Suppliers should first confirm the target market, buyer identity, project purpose and registration stage. Then they can decide which documents to send first, and which documents should be provided later after further review or confidentiality arrangements.

In pharmaceutical export, document sharing is not just about sending attachments. If too little is shared, the buyer cannot see the supplier’s support capability. If too much is shared too early, the supplier may lose control over important documents. Providing documents in layers according to the project stage makes the communication more stable and also helps suppliers judge whether the inquiry is worth continued investment.

By editor